New Data on Cimzia certolizumab pegol to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease

ATLANTA Oct. 31 2011 PRNewswire UCB a leading biopharmaceutical company at the forefront of immunology treatment and research will present new data on Cimzia&174; certolizumab pegol at the American College of Gastroenterology ACG Annual Scientific Mee...